Lexaria Bioscience Revenue Growth Rates (LEXX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Lexaria Bioscience Corp   (NASDAQ: LEXX)
 

LEXX's Revenue Growth by Quarter and Year

Lexaria Bioscience 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LEXX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter August -
3rd Quarter May 0.00
2nd Quarter February 0.02
1st Quarter November 0.00
FY 0.02

LEXXs Annual Revenue
Lexaria Bioscience 's Revenue in the fiscal year 2025 $ 0.71 millions
Lexaria Bioscience 's Revenue in the fiscal year 2024 $ 0.46 millions
Lexaria Bioscience 's Revenue in the fiscal year 2023 $ 0.23 millions
Lexaria Bioscience 's Revenue in the fiscal year 2022 $ 0.26 millions
Lexaria Bioscience 's Revenue in the fiscal year 2021 $ 0.72 millions




LEXX Revenue third quarter 2026 Y/Y Growth Comment
Lexaria Bioscience Corp in the third quarter 2026 recorded of $ 0.00 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 69 other companies have achieved higher Revenue growth. While Lexaria Bioscience Corp ' s Revenue meltdown of -100% ranks overall at the positon no. 904 in the third quarter 2026.


LEXX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter August - 112.5 % - -
3rd Quarter May - 112.5 % -11.11 % -10 %
2nd Quarter February -88.24 % 13.33 % 275 % 33.33 %
1st Quarter November - 20 % 50 % 900 %
FY   - 50 % 100 % -

Financial Statements
Lexaria Bioscience 's third quarter 2026 Revenue $ 0.00 millions LEXX's Income Statement
Lexaria Bioscience 's third quarter 2025 Revenue $ 0.17 millions Quarterly LEXX's Income Statement


LEXX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter August - 0 % 0 % -
3rd Quarter May - 0 % -46.67 % 125 %
2nd Quarter February - -5.56 % 0 % -60 %
1st Quarter November - 125 % - -9.09 %
FY (Year on Year)   - 50 % 100 % -


Back to LEXX Growth rate Comparisons >> Back to LEXX Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #70
Healthcare Sector #188
Overall #904

Revenue Y/Y Growth Statistics
High Average Low
132.93 % -117.9 % -1354.27 %
(Nov 30 2020)   (Aug 31 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #70
Healthcare Sector #188
Overall #904
Revenue Y/Y Growth Statistics
High Average Low
132.93 % -117.9 % -1354.27 %
(Nov 30 2020)   (Aug 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Lexaria Bioscience 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LEXX's III. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Lexaria Bioscience Corp come out even worse considering the 0.02 millions a quarter before.

Within Major Pharmaceutical Preparations industry Lexaria Bioscience Corp achieved highest sequential Revenue growth. While Lexaria Bioscience 's Revenue growth quarter on quarter, overall rank is .


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LEXX's III. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Lexaria Bioscience Corp come out even worse considering the 0.02 millions a quarter before.

Within Major Pharmaceutical Preparations industry Lexaria Bioscience Corp achieved highest sequential Revenue growth. While Lexaria Bioscience 's Revenue growth quarter on quarter, overall rank is .


Lexaria Bioscience 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(May 31 2026)		 12 Months Ending
(Feb 28 2026)		 12 Months Ending
(Nov 30 2025)		 12 Months Ending
(Aug 31 2025)		 12 Months Ending
(May 31 2025)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.71 $ 0.62
Y / Y Revenue Growth (TTM) - - - 52.05 % 63.44 %
Year on Year Revenue Growth Overall Ranking # 292 # 3 # 3 # 206 # 0
Seqeuential Revenue Change (TTM) - - - 14.61 % 17.11 %
Seq. Revenue Growth (TTM) Overall Ranking # 904 # 31 # 1141 # 1328 # 101


Cumulative Revenue growth Comment
Lexaria Bioscience Corp realized trailing twelve months of $ 0 millions, in the May 31 2026, compare to Revenue of $ 1 millions a year ago.

In the Healthcare sector 84 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3 to 292.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 70
Healthcare Sector # 85
Overall # 292

Revenue TTM Y/Y Growth Statistics
High Average Low
132.93 %
 -117.9 %
-1354.27 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 70
Sector # 188
S&P 500 # 904
Cumulative Revenue growth Comment
Lexaria Bioscience Corp realized trailing twelve months of $ 0 millions, in the May 31 2026, compare to Revenue of $ 1 millions a year ago.

In the Healthcare sector 84 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3 to 292.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 70
Healthcare Sector # 85
Overall # 292

Revenue TTM Y/Y Growth Statistics
High Average Low
132.93 %
-117.9 %
-1354.27 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 70
Sector # 188
S&P 500 # 904




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LEXX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue meltdown for the quarter ending May 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending May 31 2026
Neogen Corporation-0.58%$ -0.581 millions
Cryo cell International Inc -1.93%$ -1.926 millions
Nurix Therapeutics Inc -79.47%$ -79.474 millions


About Lexaria Bioscience Revenue Growth Rates (LEXX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Lexaria Bioscience Corp (CIK 1348362).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001640334-26-001166
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Lexaria Bioscience Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.